Centiva Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Centiva Capital’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10,500	Closed	-$2.55M	–	2098
2024 Q2	$2.55M	Buy	+10,500	New	+$1.66M	0.04%	306
2022 Q4	–	Sell	-1,200	Closed	-$240K	–	1346
2022 Q3	$240K	Hold	1,200	–	–	﹤0.01%	1115
2022 Q2	$175K	Buy	+1,200	New	+$170K	﹤0.01%	1322
2021 Q1	–	Sell	-2,700	Closed	-$351K	–	1133
2020 Q4	$351K	Hold	2,700	–	–	0.01%	597
2020 Q3	$393K	Hold	2,700	–	–	0.03%	409
2020 Q2	$400K	Hold	2,700	–	–	0.02%	343
2020 Q1	$293K	Sell	2,700 -600	-18%	-$69.3K	0.01%	390
2019 Q4	$381K	Hold	3,300	–	–	0.02%	506
2019 Q3	$265K	Buy	+3,300	New	+$261K	0.02%	456

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Centiva Capital's ALNY Position: Q4 2024 in Review

Centiva Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2024, closing a stake of 42 shares — an estimated $11.6K sold.

Centiva Capital first reported a position in ALNY in Q3 2019 and held it in 13 quarters. The position peaked at $793K in Q2 2021. 594 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

Centiva Capital reported no remaining Alnylam Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Centiva Capital sold 42 Alnylam Pharmaceuticals shares in Q4 2024, an estimated $11.6K.
Centiva Capital first reported a position in Alnylam Pharmaceuticals in Q3 2019 and held it in 13 quarters.
Centiva Capital's Alnylam Pharmaceuticals position peaked at $793K in Q2 2021.
594 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on Centiva Capital's 13F filing for Q4 2024, filed 14 Feb 2025.